Sermorelin
Clinical data | |
---|---|
Trade names | Geref, Gerel |
Other names | GRF 1–29 |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Injection |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C149H246N44O42S |
Molar mass | 3357.93 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Sermorelin acetate (INN ; brand names Geref, Gerel), also known as GHRH (1-29), is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency.[1][2][3] It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH.[1]
See also
[edit]References
[edit]- ^ a b Prakash A, Goa KL (August 1999). "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency". BioDrugs. 12 (2): 139–157. doi:10.2165/00063030-199912020-00007. PMID 18031173. S2CID 195690081.
- ^ Walker RF (2006). "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?". Clinical Interventions in Aging. 1 (4): 307–308. doi:10.2147/ciia.2006.1.4.307. PMC 2699646. PMID 18046908.
- ^ Rang HP, Dale MM, Ritter JM, Moore PK (2003). Pharmacology (5th ed.). Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4.